*Best friends forever*
submitted by /u/White_Power_Hacker to r/Awww [link] [comments]
[Read more...](https://www.reddit.com/r/Awww/comments/19detj1/best_friends_forever/)
submitted by /u/White_Power_Hacker to r/Awww [link] [comments]
[Read more...](https://www.reddit.com/r/Awww/comments/19detj1/best_friends_forever/)
Reddit
From the Awww community on Reddit: Best friends forever
Explore this post and more from the Awww community
*Sheβs gunna be fΓΌhrious*
submitted by /u/gaping-bingus to r/rareinsults [link] [comments]
[Read more...](https://www.reddit.com/r/rareinsults/comments/19dgvlg/shes_gunna_be_f%C3%BChrious/)
submitted by /u/gaping-bingus to r/rareinsults [link] [comments]
[Read more...](https://www.reddit.com/r/rareinsults/comments/19dgvlg/shes_gunna_be_f%C3%BChrious/)
Reddit
From the rareinsults community on Reddit: Sheβs gunna be fΓΌhrious
Explore this post and more from the rareinsults community
*Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings*
Updated at 7:16 AM EST Johnson & Johnson (JNJ) - Get Free Report posted modestly better-than-expected fourth-quarter earnings Tuesday, while reiterating its full-year profit forecast, thanks to solid sales for its psoriasis and cancer therapies. Adjusted earnings for the three months ended in December were $2.29 a share, down 2.6% from the same period in 2022 but a penny ahead of the Wall Street consensus forecast. Related: Humana plunges on major health insurance warning; UnitedHealth, CVS tumble Group revenue, Johnson & Johnson said, slipped 9.7% to $21.4 billion, exceeding analysts' estimates of a $21 billion tally. Pharmaceutical sales were up 5.4% to $13.72 billion while Medtech sales jumped 13% to $7.67 billion. Consumer health sales were spun off to Kenvue, the group's stand-alone entity, in early 2023. Johnson & Johnson reiterated that 2024 earnings should come in around $10.55 to $10.75 a share. Operational sales are expected to rise 5% to 6%, suggesting a tally between $88.2 billion and $89 billion. The new figures exclude the impact of Kenvue.J&J CEO: Entering '24 in 'position of strength' "Johnson & Johnsonβs full-year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,β said CEO Joaquin Duato. βWe have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.β Johnson & Johnson shares were marked 0.23% lower in premarket trading immediately following the earnings release to indicate an opening bell price of $162.10 each, a move that would extend the stock's six-month decline to around 5.3%. Earlier this month, Johnson & Johnson said it would pay $28 a share in cash for cancer-drug specialists Ambx Biopharma (AMAM) - Get Free Report, a deal that values the La Jolla, Calif., biotech at around $2 billion. Ambrx focuses on so-called antibody drug conjugates, which attack cancer cells from the outside without damaging healthy tissues in the rest of the body. The group has used its techniques to target breast cancer and prostate cancer in recent clinical trials and has won fast-track designation for its ARX517 prostate therapy from the U.S. Food and Drug Administration.Related: Veteran fund manager picks favorite stocks for 2024
[Read more...](https://www.thestreet.com/investing/stocks/johnson-johnson-holds-2024-profit-forecast-steady-after-solid-q4-earnings)
Updated at 7:16 AM EST Johnson & Johnson (JNJ) - Get Free Report posted modestly better-than-expected fourth-quarter earnings Tuesday, while reiterating its full-year profit forecast, thanks to solid sales for its psoriasis and cancer therapies. Adjusted earnings for the three months ended in December were $2.29 a share, down 2.6% from the same period in 2022 but a penny ahead of the Wall Street consensus forecast. Related: Humana plunges on major health insurance warning; UnitedHealth, CVS tumble Group revenue, Johnson & Johnson said, slipped 9.7% to $21.4 billion, exceeding analysts' estimates of a $21 billion tally. Pharmaceutical sales were up 5.4% to $13.72 billion while Medtech sales jumped 13% to $7.67 billion. Consumer health sales were spun off to Kenvue, the group's stand-alone entity, in early 2023. Johnson & Johnson reiterated that 2024 earnings should come in around $10.55 to $10.75 a share. Operational sales are expected to rise 5% to 6%, suggesting a tally between $88.2 billion and $89 billion. The new figures exclude the impact of Kenvue.J&J CEO: Entering '24 in 'position of strength' "Johnson & Johnsonβs full-year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,β said CEO Joaquin Duato. βWe have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.β Johnson & Johnson shares were marked 0.23% lower in premarket trading immediately following the earnings release to indicate an opening bell price of $162.10 each, a move that would extend the stock's six-month decline to around 5.3%. Earlier this month, Johnson & Johnson said it would pay $28 a share in cash for cancer-drug specialists Ambx Biopharma (AMAM) - Get Free Report, a deal that values the La Jolla, Calif., biotech at around $2 billion. Ambrx focuses on so-called antibody drug conjugates, which attack cancer cells from the outside without damaging healthy tissues in the rest of the body. The group has used its techniques to target breast cancer and prostate cancer in recent clinical trials and has won fast-track designation for its ARX517 prostate therapy from the U.S. Food and Drug Administration.Related: Veteran fund manager picks favorite stocks for 2024
[Read more...](https://www.thestreet.com/investing/stocks/johnson-johnson-holds-2024-profit-forecast-steady-after-solid-q4-earnings)
TheStreet
Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings
Johnson & Johnson says its on track to meet its 2025 target of $57 billion in pharmaceutical sales.
*Verizon leaps as key factor in outlook adds fuel to Q4 earnings beat*
Verizon (VZ) - Get Free Report posted better-than-expected fourth quarter earnings Tuesday, while forecasting solid 2024 profits thanks in part to its flexible wireless plans and promotions linked to Apple's (AAPL) - Get Free Report new iPhone 15. Adjusted non-GAAP earnings for the three months ended in December were $1.08 a share, down 9.2% from the same period in 2022 but topping the Wall Street consensus forecast of $1.07 per share. Related: Iconic retailer rejects multibillion-dollar takeover bid Group revenue, Verizon said, slipped 0.4% from a year earlier to $35.1 billion, just ahead of analysts' estimates of a $34.58 billion tally. Verzion's postpaid additions for the quarter were pegged at 446,000, the highest in nearly two years and double analysts' estimates. That's thanks in part to hybrid plans that include streaming subscriptions such as Netflix (NFLX) - Get Free Report and Max. (WBD) - Get Free Report Looking into the coming year, Verizon sees wireless revenue growing 2% to 3.5%. Adjusted earnings are estimated in the region of $4.50 to $4.70 per share, compared with an LSEG forecast of around $4.59 per share.Verizon CEO: Balance of growth, profitability "After delivering continuous improvement throughout 2023, we ended the year strong and continue to pursue the right balance of growth and profitability," Chief Executive Hans Vestberg said in a statement. Shutterstock The year "2023 was a year of change. We have the right assets and the best team in place and are well-positioned for growth in 2024." Verizon shares were marked 1.6% higher in premarket trading immediately following the earnings release to indicate an opening bell price of $40.20 each. Technology:AI takes this stock to record; investors look past Magnificent 7 Amazon plan to paywall a popular product hits a roadblock AI stock soars on new guidance (it's not Nvidia!) Last November, the group named Tony Skiadas as full-time chief financial office. Vestberg said the move positioned the company veteran "to steer us through the current economic volatility and our industry's changing landscape." Verizon's ongoing deployment of its 5G network, built in part on the $53 billion purchase of new C-Band spectrum from the U.S. government, remains a key plank in the group's growth prospects Related: Veteran fund manager picks favorite stocks for 2024
[Read more...](https://www.thestreet.com/investing/stocks/verizon-leaps-as-2024-subscriber-outlook-adds-fuel-to-q4-earnings-beat)
Verizon (VZ) - Get Free Report posted better-than-expected fourth quarter earnings Tuesday, while forecasting solid 2024 profits thanks in part to its flexible wireless plans and promotions linked to Apple's (AAPL) - Get Free Report new iPhone 15. Adjusted non-GAAP earnings for the three months ended in December were $1.08 a share, down 9.2% from the same period in 2022 but topping the Wall Street consensus forecast of $1.07 per share. Related: Iconic retailer rejects multibillion-dollar takeover bid Group revenue, Verizon said, slipped 0.4% from a year earlier to $35.1 billion, just ahead of analysts' estimates of a $34.58 billion tally. Verzion's postpaid additions for the quarter were pegged at 446,000, the highest in nearly two years and double analysts' estimates. That's thanks in part to hybrid plans that include streaming subscriptions such as Netflix (NFLX) - Get Free Report and Max. (WBD) - Get Free Report Looking into the coming year, Verizon sees wireless revenue growing 2% to 3.5%. Adjusted earnings are estimated in the region of $4.50 to $4.70 per share, compared with an LSEG forecast of around $4.59 per share.Verizon CEO: Balance of growth, profitability "After delivering continuous improvement throughout 2023, we ended the year strong and continue to pursue the right balance of growth and profitability," Chief Executive Hans Vestberg said in a statement. Shutterstock The year "2023 was a year of change. We have the right assets and the best team in place and are well-positioned for growth in 2024." Verizon shares were marked 1.6% higher in premarket trading immediately following the earnings release to indicate an opening bell price of $40.20 each. Technology:AI takes this stock to record; investors look past Magnificent 7 Amazon plan to paywall a popular product hits a roadblock AI stock soars on new guidance (it's not Nvidia!) Last November, the group named Tony Skiadas as full-time chief financial office. Vestberg said the move positioned the company veteran "to steer us through the current economic volatility and our industry's changing landscape." Verizon's ongoing deployment of its 5G network, built in part on the $53 billion purchase of new C-Band spectrum from the U.S. government, remains a key plank in the group's growth prospects Related: Veteran fund manager picks favorite stocks for 2024
[Read more...](https://www.thestreet.com/investing/stocks/verizon-leaps-as-2024-subscriber-outlook-adds-fuel-to-q4-earnings-beat)
TheStreet
Verizon leaps as key factor in outlook adds fuel to Q4 earnings beat
In the fourth quarter Verizon leveraged the strength of its promotions and the launch of Apple's iPhone 15.
Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings
Updated at 7:16 AM EST Johnson & Johnson (JNJ) - Get Free Report posted modestly better-than-expected fourth-quarter earnings Tuesday, while reiterating its full-year profit forecast, thanks to solid sales for its psoriasis and cancer therapies. Adjusted earnings for the three months ended in December were $2.29 a share, down 2.6% from the same period in 2022 but a penny ahead of the Wall Street consensus forecast. Related: Humana plunges on major health insurance warning; UnitedHealth, CVS tumble Group revenue, Johnson & Johnson said, slipped 9.7% to $21.4 billion, exceeding analysts' estimates of a $21 billion tally. Pharmaceutical sales were up 5.4% to $13.72 billion while Medtech sales jumped 13% to $7.67 billion. Consumer health sales were spun off to Kenvue, the group's stand-alone entity, in early 2023. Johnson & Johnson reiterated that 2024 earnings should come in around $10.55 to $10.75 a share. Operational sales are expected to rise 5% to 6%, suggesting a tally between $88.2 billion and $89 billion. The new figures exclude the impact of Kenvue.J&J CEO: Entering '24 in 'position of strength' "Johnson & Johnsonβs full-year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,β said CEO Joaquin Duato. βWe have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.β Johnson & Johnson shares were marked 0.23% lower in premarket trading immediately following the earnings release to indicate an opening bell price of $162.10 each, a move that would extend the stock's six-month decline to around 5.3%. Earlier this month, Johnson & Johnson said it would pay $28 a share in cash for cancer-drug specialists Ambx Biopharma (AMAM) - Get Free Report, a deal that values the La Jolla, Calif., biotech at around $2 billion. Ambrx focuses on so-called antibody drug conjugates, which attack cancer cells from the outside without damaging healthy tissues in the rest of the body. The group has used its techniques to target breast cancer and prostate cancer in recent clinical trials and has won fast-track designation for its ARX517 prostate therapy from the U.S. Food and Drug Administration.Related: Veteran fund manager picks favorite stocks for 2024
Read more...
Updated at 7:16 AM EST Johnson & Johnson (JNJ) - Get Free Report posted modestly better-than-expected fourth-quarter earnings Tuesday, while reiterating its full-year profit forecast, thanks to solid sales for its psoriasis and cancer therapies. Adjusted earnings for the three months ended in December were $2.29 a share, down 2.6% from the same period in 2022 but a penny ahead of the Wall Street consensus forecast. Related: Humana plunges on major health insurance warning; UnitedHealth, CVS tumble Group revenue, Johnson & Johnson said, slipped 9.7% to $21.4 billion, exceeding analysts' estimates of a $21 billion tally. Pharmaceutical sales were up 5.4% to $13.72 billion while Medtech sales jumped 13% to $7.67 billion. Consumer health sales were spun off to Kenvue, the group's stand-alone entity, in early 2023. Johnson & Johnson reiterated that 2024 earnings should come in around $10.55 to $10.75 a share. Operational sales are expected to rise 5% to 6%, suggesting a tally between $88.2 billion and $89 billion. The new figures exclude the impact of Kenvue.J&J CEO: Entering '24 in 'position of strength' "Johnson & Johnsonβs full-year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,β said CEO Joaquin Duato. βWe have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.β Johnson & Johnson shares were marked 0.23% lower in premarket trading immediately following the earnings release to indicate an opening bell price of $162.10 each, a move that would extend the stock's six-month decline to around 5.3%. Earlier this month, Johnson & Johnson said it would pay $28 a share in cash for cancer-drug specialists Ambx Biopharma (AMAM) - Get Free Report, a deal that values the La Jolla, Calif., biotech at around $2 billion. Ambrx focuses on so-called antibody drug conjugates, which attack cancer cells from the outside without damaging healthy tissues in the rest of the body. The group has used its techniques to target breast cancer and prostate cancer in recent clinical trials and has won fast-track designation for its ARX517 prostate therapy from the U.S. Food and Drug Administration.Related: Veteran fund manager picks favorite stocks for 2024
Read more...
TheStreet
Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings
Johnson & Johnson says its on track to meet its 2025 target of $57 billion in pharmaceutical sales.
Verizon leaps as key factor in outlook adds fuel to Q4 earnings beat
Verizon (VZ) - Get Free Report posted better-than-expected fourth quarter earnings Tuesday, while forecasting solid 2024 profits thanks in part to its flexible wireless plans and promotions linked to Apple's (AAPL) - Get Free Report new iPhone 15. Adjusted non-GAAP earnings for the three months ended in December were $1.08 a share, down 9.2% from the same period in 2022 but topping the Wall Street consensus forecast of $1.07 per share. Related: Iconic retailer rejects multibillion-dollar takeover bid Group revenue, Verizon said, slipped 0.4% from a year earlier to $35.1 billion, just ahead of analysts' estimates of a $34.58 billion tally. Verzion's postpaid additions for the quarter were pegged at 446,000, the highest in nearly two years and double analysts' estimates. That's thanks in part to hybrid plans that include streaming subscriptions such as Netflix (NFLX) - Get Free Report and Max. (WBD) - Get Free Report Looking into the coming year, Verizon sees wireless revenue growing 2% to 3.5%. Adjusted earnings are estimated in the region of $4.50 to $4.70 per share, compared with an LSEG forecast of around $4.59 per share.Verizon CEO: Balance of growth, profitability "After delivering continuous improvement throughout 2023, we ended the year strong and continue to pursue the right balance of growth and profitability," Chief Executive Hans Vestberg said in a statement. Shutterstock The year "2023 was a year of change. We have the right assets and the best team in place and are well-positioned for growth in 2024." Verizon shares were marked 1.6% higher in premarket trading immediately following the earnings release to indicate an opening bell price of $40.20 each. Technology:AI takes this stock to record; investors look past Magnificent 7 Amazon plan to paywall a popular product hits a roadblock AI stock soars on new guidance (it's not Nvidia!) Last November, the group named Tony Skiadas as full-time chief financial office. Vestberg said the move positioned the company veteran "to steer us through the current economic volatility and our industry's changing landscape." Verizon's ongoing deployment of its 5G network, built in part on the $53 billion purchase of new C-Band spectrum from the U.S. government, remains a key plank in the group's growth prospects Related: Veteran fund manager picks favorite stocks for 2024
Read more...
Verizon (VZ) - Get Free Report posted better-than-expected fourth quarter earnings Tuesday, while forecasting solid 2024 profits thanks in part to its flexible wireless plans and promotions linked to Apple's (AAPL) - Get Free Report new iPhone 15. Adjusted non-GAAP earnings for the three months ended in December were $1.08 a share, down 9.2% from the same period in 2022 but topping the Wall Street consensus forecast of $1.07 per share. Related: Iconic retailer rejects multibillion-dollar takeover bid Group revenue, Verizon said, slipped 0.4% from a year earlier to $35.1 billion, just ahead of analysts' estimates of a $34.58 billion tally. Verzion's postpaid additions for the quarter were pegged at 446,000, the highest in nearly two years and double analysts' estimates. That's thanks in part to hybrid plans that include streaming subscriptions such as Netflix (NFLX) - Get Free Report and Max. (WBD) - Get Free Report Looking into the coming year, Verizon sees wireless revenue growing 2% to 3.5%. Adjusted earnings are estimated in the region of $4.50 to $4.70 per share, compared with an LSEG forecast of around $4.59 per share.Verizon CEO: Balance of growth, profitability "After delivering continuous improvement throughout 2023, we ended the year strong and continue to pursue the right balance of growth and profitability," Chief Executive Hans Vestberg said in a statement. Shutterstock The year "2023 was a year of change. We have the right assets and the best team in place and are well-positioned for growth in 2024." Verizon shares were marked 1.6% higher in premarket trading immediately following the earnings release to indicate an opening bell price of $40.20 each. Technology:AI takes this stock to record; investors look past Magnificent 7 Amazon plan to paywall a popular product hits a roadblock AI stock soars on new guidance (it's not Nvidia!) Last November, the group named Tony Skiadas as full-time chief financial office. Vestberg said the move positioned the company veteran "to steer us through the current economic volatility and our industry's changing landscape." Verizon's ongoing deployment of its 5G network, built in part on the $53 billion purchase of new C-Band spectrum from the U.S. government, remains a key plank in the group's growth prospects Related: Veteran fund manager picks favorite stocks for 2024
Read more...
TheStreet
Verizon leaps as key factor in outlook adds fuel to Q4 earnings beat
In the fourth quarter Verizon leveraged the strength of its promotions and the launch of Apple's iPhone 15.
*ΠΠ±Π·ΠΎΡ Huawei MatePad Pro 13.2β³ β ΡΠ»Π°Π³ΠΌΠ°Π½ΡΠΊΠΎΠ³ΠΎ ΠΏΠ»Π°Π½ΡΠ΅ΡΠ° Π½Π° Π·Π°ΠΌΠ΅Π½Ρ Π½ΠΎΡΡΠ±ΡΠΊΡ*
Π ΠΏΠ°ΡΠ΅ Ρ ΠΊΠ»Π°Π²ΠΈΠ°ΡΡΡΠΎΠΉ Π³Π°Π΄ΠΆΠ΅Ρ ΠΏΡΠ΅Π²ΡΠ°ΡΠ°Π΅ΡΡΡ Π² ΡΠ΄ΠΎΠ±Π½ΡΠΉ ΡΠ°Π±ΠΎΡΠΈΠΉ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½Ρ, Π° Π²ΠΎΡ Π΄Π»Ρ ΠΈΠ³Ρ ΠΌΠΎΠΆΠ΅Ρ Π½Π΅ ΠΏΠΎΠ΄ΠΎΠΉΡΠΈ.
[Read more...](https://lifehacker.ru/obzor-huawei-matepad-pro-13-2/)
Π ΠΏΠ°ΡΠ΅ Ρ ΠΊΠ»Π°Π²ΠΈΠ°ΡΡΡΠΎΠΉ Π³Π°Π΄ΠΆΠ΅Ρ ΠΏΡΠ΅Π²ΡΠ°ΡΠ°Π΅ΡΡΡ Π² ΡΠ΄ΠΎΠ±Π½ΡΠΉ ΡΠ°Π±ΠΎΡΠΈΠΉ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½Ρ, Π° Π²ΠΎΡ Π΄Π»Ρ ΠΈΠ³Ρ ΠΌΠΎΠΆΠ΅Ρ Π½Π΅ ΠΏΠΎΠ΄ΠΎΠΉΡΠΈ.
[Read more...](https://lifehacker.ru/obzor-huawei-matepad-pro-13-2/)
*You're now a Dev for Wilds. How would you change your main weapon?*
submitted by /u/Tech-Demon to r/MonsterHunter [link] [comments]
[Read more...](https://www.reddit.com/r/MonsterHunter/comments/19d8qsk/youre_now_a_dev_for_wilds_how_would_you_change/)
submitted by /u/Tech-Demon to r/MonsterHunter [link] [comments]
[Read more...](https://www.reddit.com/r/MonsterHunter/comments/19d8qsk/youre_now_a_dev_for_wilds_how_would_you_change/)
Reddit
From the MonsterHunter community on Reddit: You're now a Dev for Wilds. How would you change your main weapon?
Explore this post and more from the MonsterHunter community
You're now a Dev for Wilds. How would you change your main weapon?
submitted by /u/Tech-Demon to r/MonsterHunter link comments
Read more...
submitted by /u/Tech-Demon to r/MonsterHunter link comments
Read more...
Reddit
From the MonsterHunter community on Reddit: You're now a Dev for Wilds. How would you change your main weapon?
Explore this post and more from the MonsterHunter community
*ΠΠΎΠ΅Π½Π½ΡΠ΅ ΡΠΈΠ½Ρ ΠΈ Π·Π½Π°ΠΊΠΈ*
via forma full 5 https://ift.tt/fZw8iBY Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3595635.html)
via forma full 5 https://ift.tt/fZw8iBY Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3595635.html)
Forma-Odezhda
ΠΠΎΠ΅Π½Π½ΡΠ΅ ΡΠΈΠ½Ρ ΠΈ Π·Π½Π°ΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π°ΡΠΌΠΈΠΈ ΠΠ°ΠΏΠΎΠ»Π΅ΠΎΠ½Π°
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠΎΠ΅Π½Π½ΡΠ΅ ΡΠΈΠ½Ρ ΠΈ Π·Π½Π°ΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π°ΡΠΌΠΈΠΈ ΠΠ°ΠΏΠΎΠ»Π΅ΠΎΠ½Π° Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΠΎΠ΅Π½Π½ΡΠ΅ ΡΠΈΠ½Ρ ΠΈ Π·Π½Π°ΠΊΠΈ
via forma full 5 https://ift.tt/fZw8iBY Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/fZw8iBY Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠΎΠ΅Π½Π½ΡΠ΅ ΡΠΈΠ½Ρ ΠΈ Π·Π½Π°ΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π°ΡΠΌΠΈΠΈ ΠΠ°ΠΏΠΎΠ»Π΅ΠΎΠ½Π°
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠΎΠ΅Π½Π½ΡΠ΅ ΡΠΈΠ½Ρ ΠΈ Π·Π½Π°ΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π°ΡΠΌΠΈΠΈ ΠΠ°ΠΏΠΎΠ»Π΅ΠΎΠ½Π° Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*Π€ΠΎΡΠΌΠ΅Π½Π½Π°Ρ ΠΎΠ΄Π΅ΠΆΠ΄Π° ΠΠΠ‘*
via forma full 5 https://ift.tt/KBI2W7A Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3599964.html)
via forma full 5 https://ift.tt/KBI2W7A Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3599964.html)
Forma-Odezhda
Π€ΠΎΡΠΌΠ΅Π½Π½Π°Ρ ΠΎΠ΄Π΅ΠΆΠ΄Π° ΠΠΠ‘
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ Π€ΠΎΡΠΌΠ΅Π½Π½Π°Ρ ΠΎΠ΄Π΅ΠΆΠ΄Π° ΠΠΠ‘ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
Π€ΠΎΡΠΌΠ΅Π½Π½Π°Ρ ΠΎΠ΄Π΅ΠΆΠ΄Π° ΠΠΠ‘
via forma full 5 https://ift.tt/KBI2W7A Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/KBI2W7A Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
Π€ΠΎΡΠΌΠ΅Π½Π½Π°Ρ ΠΎΠ΄Π΅ΠΆΠ΄Π° ΠΠΠ‘
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ Π€ΠΎΡΠΌΠ΅Π½Π½Π°Ρ ΠΎΠ΄Π΅ΠΆΠ΄Π° ΠΠΠ‘ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*What is this worm?*
Found in San Diego rain storm. submitted by /u/amnesiagentileschi to r/whatsthisbug [link] [comments]
[Read more...](https://www.reddit.com/r/whatsthisbug/comments/19d6doe/what_is_this_worm/)
Found in San Diego rain storm. submitted by /u/amnesiagentileschi to r/whatsthisbug [link] [comments]
[Read more...](https://www.reddit.com/r/whatsthisbug/comments/19d6doe/what_is_this_worm/)
Reddit
From the whatsthisbug community on Reddit: What is this worm?
Explore this post and more from the whatsthisbug community
What is this worm?
Found in San Diego rain storm. submitted by /u/amnesiagentileschi to r/whatsthisbug link comments
Read more...
Found in San Diego rain storm. submitted by /u/amnesiagentileschi to r/whatsthisbug link comments
Read more...
Reddit
From the whatsthisbug community on Reddit: What is this worm?
Explore this post and more from the whatsthisbug community
*ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π *
via forma full 5 https://ift.tt/mUkew0u Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3599502.html)
via forma full 5 https://ift.tt/mUkew0u Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3599502.html)
Forma-Odezhda
ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π
via forma full 5 https://ift.tt/mUkew0u Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/mUkew0u Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*HP ΠΎΠ±ΡΡΡΠ½ΠΈΠ»Π°, ΠΏΠΎΡΠ΅ΠΌΡ Π² ΠΏΡΠΈΠ½ΡΠ΅ΡΡ Π½Π΅Π»ΡΠ·Ρ Π·Π°Π³ΡΡΠΆΠ°ΡΡ Π½Π΅ΠΎΡΠΈΠ³ΠΈΠ½Π°Π»ΡΠ½ΡΠ΅ ΠΊΠ°ΡΡΡΠΈΠ΄ΠΆΠΈ*
ΠΡΡ Π΄Π΅Π»ΠΎ Π² Π²ΠΈΡΡΡΠ°Ρ . Π£Π΄ΠΈΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎ, ΡΡΠΎ ΠΊ Π»ΠΈΡΠ΅Π½Π·ΠΈΠΎΠ½Π½ΡΠΌ ΡΠ΅ΡΠ½ΠΈΠ»Π°ΠΌ Π½Π΅ ΠΏΡΠΈΠΊΠ»Π°Π΄ΡΠ²Π°ΡΡ ΡΠ°ΠΏΠΎΡΠΊΡ ΠΈΠ· ΡΠΎΠ»ΡΠ³ΠΈ.
[Read more...](https://lifehacker.ru/hp-pro-neoriginalnye-kartridzhi/)
ΠΡΡ Π΄Π΅Π»ΠΎ Π² Π²ΠΈΡΡΡΠ°Ρ . Π£Π΄ΠΈΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎ, ΡΡΠΎ ΠΊ Π»ΠΈΡΠ΅Π½Π·ΠΈΠΎΠ½Π½ΡΠΌ ΡΠ΅ΡΠ½ΠΈΠ»Π°ΠΌ Π½Π΅ ΠΏΡΠΈΠΊΠ»Π°Π΄ΡΠ²Π°ΡΡ ΡΠ°ΠΏΠΎΡΠΊΡ ΠΈΠ· ΡΠΎΠ»ΡΠ³ΠΈ.
[Read more...](https://lifehacker.ru/hp-pro-neoriginalnye-kartridzhi/)